By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in ...

Dividend Growth: CVS has increased its dividend by 142% over the past decade, with a current forward yield of 4.64%. This significantly surpasses the S&P 500 average of 1.35%.

CVS to Exclusively Distribute Gilead Sciences's $1,000-Per-Pill Hepatitis C Treatment Published Jan 06, 2015 at 5:02 PM EST Updated Mar 12, 2016 at 9:16 AM EST ...

The battle for supremacy in one of the fastest-growing pharmaceutical markets intensified on Monday, with CVS Health Corp. saying it will make Gilead Sciences Inc.’s drugs Sovaldi and Harvoni ...

Gilead Sciences agreed to make its hepatitis C medicines the exclusive treatments for CVS Health customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.

CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid.